Chronic Low Back Pain Clinical Trial
Official title:
Investigating the Hypoalgesic Effects of Spinal Manipulative Therapy Using Hidden Pain Conditioning and Positive Expectation in Chronic Low Back Pain Patients: Protocol for a Randomized Controlled Trial
The objective of this study will be to identify whether a conditioning procedure by the surreptitious downgrade of a noxious stimulus intensity associated with induced positive expectations about treatment will result in greater hypoalgesic effects when compared to positive verbal suggestions (positive expectation induction) alone regarding the effects of spinal manipulative therapy intervention in patients with CLBP. This study will enroll 264 individuals with CLBP aged between 18 and 60 years. Spinal Manipulative Therapy in the lumbar spine will be administered to all participants during 5 sessions. First assessment session - participants will be submitted to a quantitative sensory testing (QST) to determine the heat pain threshold (calibration test) to run the conditioning procedure. Afterward, participants will be allocated by a blinded researcher into the following subgroups: hidden conditioning + positive expectation (G1); positive expectation alone (G2) and a group submitted to neutral expectations (G3) about the treatment. First treatment session - Firstly, participants will receive instructions with the aim to induce positive (or neutral) expectations by means of a workshop. Secondly, all the participants will be submitted again to the pre-conditioning test, using the more intense pain stimulus obtained in the calibration test, then patients will be assessed regarding pain intensity and finally submitted to the manipulative therapy. At the end of the first treatment session, the conditioning test will be repeated, but the heat pain threshold of the hidden conditioning group (G1) will be surreptitiously downgraded (from intense pain stimulus to moderate pain stimulus) as a means of conditioning patients to believe that manipulative therapy promoted pain relief. Pain intensity will be assessed again to confirm a decrease in pain intensity. Outcomes will be assessed three times: immediately after the five therapy sessions, one month later, and three months later. The primary outcomes assessed will be pain intensity and global perceived effect of improvement. The secondary outcome will be low back pain disability.
Status | Recruiting |
Enrollment | 264 |
Est. completion date | March 10, 2024 |
Est. primary completion date | December 10, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: The inclusion criteria for patients were as follows: 1. Patients who report non-specific CLBP (in which the specific nociceptive source cannot be identified, confirmed by a medical assessment) for at least three months duration; 2. Age ranged from 18 years to 60 years 3. Baseline pain intensity score =3 on a Numeric Pain Rating Scale (NPRS) (because of the measurement error > 2 reported for the NPRS); 4. Score greater than 14% on the Oswestry Disability Index (ODI) (to surpass the smallest detectable change of the ODI total score 5. Patients able to speak and understand Portuguese well to fill out the questionnaires. Patients will be excluded if they met any of the following criteria: 1. Previous poor experiences with SMT through the application of a brief screening questionnaire 2. Pregnancy 3. Specific low back pain disorders like radiculopathy or lumbar stenosis or chronic degenerative disorders, i.e., uncontrolled cardiovascular, metabolic, or systemic diseases, neurological or psychiatric diseases, and stroke sequelae 4. Undergoing other therapeutic interventions for chronic pain and low back pain (including surgeries) in the last 3 months 5. Presence of contraindications to SMT 6. Patients who reach the upper limit of 50ÂșC, which is the maximum temperature provided by the Q-sense equipment described in the Medoc, Israel website |
Country | Name | City | State |
---|---|---|---|
Brazil | Unidade Saúde Escola - USE | São Carlos | São Paulo |
Lead Sponsor | Collaborator |
---|---|
Universidade Federal de Sao Carlos | Fundação de Amparo à Pesquisa do Estado de São Paulo |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Stanford Expectation Treatment Scale (SETS) | The scale contains six questions and seven answer alternatives, ranging from strongly disagree, partially disagree, slightly disagree, neither agree nor disagree, slightly agree, partially agree, and entirely agree to strongly disagree, partially disagree, slightly agree, partially agree, and fully agree. The positive expectation domain must include the total of items 1, 3 and 5 (score ranging from 7-21), while the negative expectation domain must include the sum of questions 2, 4 and 6 (score ranging from 7-21). | Baseline | |
Other | Low Back Pain Improvement Expectation Scale | The Scale evaluates a patient's past estimate that his or her low back pain would get better (regardless of the treatment used)."What are the chances of receiving relief from low back pain?" the participant will be asked.The participant will be given an 11-point scale to answer on, with 0 representing "no possibility" and 10 representing "extremely probable". | Baseline | |
Other | Patient Health Questionnaire-9 (PHQ-9) | The PHQ-9 Brazilian version will be used to assess symptoms of depression. Patients will be asked to rate nine questions on a four-point scale over the two weeks before to the administration of the questionnaire in this self-report measure. Validity has been assessed against an independent structured mental health professional interview. The PHQ-9 Brazilian version showed suitable structural validity (Confirmatory Fit Index = 0.98) | Baseline | |
Other | General Anxiety Disorder-7 (GAD-7) | The GAD-7 is a widely used diagnostic self-report scale for anxiety disorder screening, diagnosis, and severity assessment. Patients will be asked to rate their anxiety-related difficulties on a four-point scale over the two weeks before to the administration of the questionnaire in this self-report measure. GAD-7 scores vary from zero to 21, with higher GAD-7 scores being linked to more severe generalized anxiety. The psychometric properties of the GAD-7 in Brazilian Portuguese showed a one-dimensional structure and good internal consistency (a = 0.88). GAD-7 Brazilian version showed suitable internal consistency (Cronbach's alpha = .916) and reliability coefficient (?= .909). | Baseline | |
Other | Tampa Scale for Kinesiophobia (TSK) | TSK is a self-report questionnaire that assesses the fear of movement through 17 items that address pain and symptom intensity. The scores for each item range from 1 to 4 points (1 point for "strongly disagree", 2 points for "partially disagree", 3 points for "agree" and 4 points for "strongly agree"). For the total score, it is necessary to invert the scores of questions 4, 8, 12 and 16. The final score can range from 17 to 68 points, higher scores represent stronger beliefs about fear of movement. | Baseline | |
Other | Pain Catastrophizing Scale (PCS) | PCS is a self-administered questionnaire that consists of 13 items for the assessment of catastrophizing thoughts. It is divided into three domains: helplessness, magnification, and rumination. Each item is scored on a 5-point ordinal scale. The B-PCS total score ranges from 0 to 52 points, higher values denote greater pain catastrophizing. Acceptable values for validity, internal consistency, and test-retest reliability are described for the Brazilian PCS. | Baseline | |
Other | Positive and Negative Affect Scales (PANAS) | PANAS will be used to assess the positive and negative affect constructs. The scale is made up of 40 items, each factor made up of 20 adjectives that represent the subjects' moods and emotions. Each adjective is rated by the patients on a five-point Likert scale. The Brazilian Portuguese demonstrated acceptable measurement properties. The scale showed suitable internal consistency (Cronbach's Alpha = 0.84) and structural validity. | Baseline | |
Other | Pain Self-Efficacy Questionnaire (PSEQ) | Study patients will be evaluated on self-efficacy related to chronic pain, which can be defined as an individual's confidence that he/she can successfully produce desirable results related to living with chronic pain. The PSEQ has ten items which are rated on a seven-point ordinal. It was cross cultural adapted and validated to Brazilian Portuguese. Previous research showed an effect on self-efficacy using a pain neuroscience education intervention based on metaphors compared to an intervention using cognitive- behavioral concepts. PSEQ Brazilian version showed suitable internal consistency (Cronbach's alpha = .90) and construct validity when compared to Roland Morris Questionnaire (r=-.58). | Baseline | |
Primary | Numeric pain rating scale (NPRS) | The NPRS used in this trial will consist of numbers from 0 to 10, in which 0 represents "no pain" and 10 represents "worst pain imaginable". High scores mean worse pain intensity. | 6 weeks after randomization | |
Primary | Global Perceived Effect (GPE) | The GPE of improvement used for this trial is an 11-point scale that ranges from - 5 ("vastly worse") through 0 ("no change") to + 5 ("completely recovered") and participants are asked: "Compared to when this episode first started, how would you describe your orofacial pain these days?". A higher score indicates higher perception of recovery from the condition. | 6 weeks after randomization | |
Secondary | Oswestry Disability Index (ODI) | The ODI consists of 10 items, each of which has six response options. The total score will be calculated by summing up all the points, ranging from 10 to 50. This sum will be transformed into a percentage (0 to 100). High scores mean worse disability. | 6 weeks and 3 months after randomization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03243084 -
Transcranial Alternating Current Stimulation in Back Pain- Pilot Sudy
|
N/A | |
Suspended |
NCT04735185 -
Stem Cells vs. Steroids for Discogenic Back Pain
|
N/A | |
Completed |
NCT03162952 -
RAND Center of Excellence for the Study of Appropriateness of Care in CAM
|
||
Completed |
NCT03240146 -
Pulsed Shortwave Therapy Treatment for Chronic Musculoskeletal Low Back Pain
|
N/A | |
Completed |
NCT05282589 -
Lumbopelvic Manipulation Effects on Fatigue in Chronic Low Back Pain Patients
|
N/A | |
Completed |
NCT03637998 -
Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain
|
N/A | |
Recruiting |
NCT02289170 -
Clinical Study to Evaluate the Safety and Efficacy of Heating and Cooling Combination Therapeutic Device(OCH-S100)
|
N/A | |
Active, not recruiting |
NCT01944163 -
The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain
|
N/A | |
Completed |
NCT02231554 -
Feldenkrais vs Back School for Treating Chronic Low Back Pain: a Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT02063503 -
Identification of Prognostic Indicators for Rehabilitation in Chronic Nonspecific Low Back Pain Patients
|
N/A | |
Terminated |
NCT01620775 -
MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain
|
N/A | |
Completed |
NCT01704677 -
Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation; 8-year Follow-up
|
N/A | |
Completed |
NCT01490905 -
A Double Blind Placebo Study to Determine the Effectiveness of Theramine on the Management of Chronic Back Pain
|
Phase 4 | |
Completed |
NCT01177280 -
Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioid Analgesics and Associated Economic Outcomes
|
N/A | |
Completed |
NCT01177241 -
Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids
|
N/A | |
Completed |
NCT01177254 -
Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions
|
N/A | |
Completed |
NCT00984815 -
Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment
|
Phase 3 | |
Completed |
NCT00767806 -
A Study for Patient With Chronic Low Back Pain
|
Phase 3 | |
Completed |
NCT00763321 -
Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
|
Phase 3 | |
Completed |
NCT00761150 -
Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
|
Phase 3 |